TrialJournal for immunotherapy of cancer2023

Evaluation of tissue- and plasma-derived tumor mutational burden (TMB) and genomic alterations of interest in CheckMate 848, a study of nivolumab combined with ipilimumab and nivolumab alone in patients with advanced or metastatic solid tumors with high TMB.

Jie He et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.